Literature DB >> 14742517

Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium.

David Baud1, Jalil Benyacoub, Véronique Revaz, Menno Kok, Françoise Ponci, Martine Bobst, Roy Curtiss, Pierre De Grandi, Denise Nardelli-Haefliger.   

Abstract

Recombinant Salmonella strains have been widely used to deliver heterologous antigens and induce immune responses in vaccinated animals and humans. It remains to be established, however, how these bacteria mount an immune response; this has prevented the rational design of vaccines. Here we report for the first time that a particular genetic program, PhoPc, is necessary for recombinant Salmonella strains to induce an antibody response to a heterologous antigen, the human papillomaviruses type 16 (HPV16) virus-like particle (VLP). The PhoPc phenotype results from a point mutation in phoQ, the gene encoding the sensor component of a two-component regulatory system (PhoP-PhoQ) that controls the expression of a number of virulence factors in Salmonellae. To demonstrate that immunogenicity of the viral antigen expressed by the bacterial vector was dependent on the PhoPc phenotype, we have expressed the phoQ mutant gene (phoQ24) in two differently attenuated Salmonella enterica serovar Typhimurium strains. Our data show extrachromosomal phoQ24 to be dominant over the chromosomal copy of the phoQ gene, conferring the PhoPc phenotype on the recipient strains. In addition, activation of PhoPQ-regulated genes by the plasmid-encoded PhoQ24 did not alter bacterial survival and conferred immunogenicity to the HPV16 VLP expressed in the two S. enterica serovar Typhimurium backgrounds, inducing the production of HPV-specific antibodies in mice. This strongly suggests that at least one of the PhoP-regulated genes is necessary for mounting an efficient antibody response to HPV16 VLP. This finding sets the stage for further development of a Salmonella-based vaccine against HPV infection and cervical cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14742517      PMCID: PMC321624          DOI: 10.1128/IAI.72.2.750-756.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

Authors:  J M Walboomers; M V Jacobs; M M Manos; F X Bosch; J A Kummer; K V Shah; P J Snijders; J Peto; C J Meijer; N Muñoz
Journal:  J Pathol       Date:  1999-09       Impact factor: 7.996

2.  PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance.

Authors:  J S Gunn; K B Lim; J Krueger; K Kim; L Guo; M Hackett; S I Miller
Journal:  Mol Microbiol       Date:  1998-03       Impact factor: 3.501

3.  Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.

Authors:  C Balmelli; R Roden; A Potts; J Schiller; P De Grandi; D Nardelli-Haefliger
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Comparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen.

Authors:  S J Dunstan; C P Simmons; R A Strugnell
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.

Authors:  J Benyacoub; S Hopkins; A Potts; S Kelly; J P Kraehenbuhl; R Curtiss; P De Grandi; D Nardelli-Haefliger
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

6.  Salmonella enterica serovar typhimurium-induced maturation of bone marrow-derived dendritic cells.

Authors:  M Svensson; C Johansson; M J Wick
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

7.  Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium.

Authors:  J S Gunn; S S Ryan; J C Van Velkinburgh; R K Ernst; S I Miller
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

8.  Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice.

Authors:  D Nardelli-Haefliger; R Roden; C Balmelli; A Potts; J Schiller; P De Grandi
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

9.  Identification of PhoP-PhoQ activated genes within a duplicated region of the Salmonella typhimurium chromosome.

Authors:  J S Gunn; W J Belden; S I Miller
Journal:  Microb Pathog       Date:  1998-08       Impact factor: 3.738

10.  Levels of expression and immunogenicity of attenuated Salmonella enterica serovar typhimurium strains expressing Escherichia coli mutant heat-labile enterotoxin.

Authors:  M G Covone; M Brocchi; E Palla; W Dias da Silveira; R Rappuoli; C L Galeotti
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

View more
  10 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 2.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

Review 3.  How will HPV vaccines affect cervical cancer?

Authors:  Richard Roden; T-C Wu
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

4.  Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.

Authors:  Heinz Arnold; Dirk Bumann; Melanie Felies; Britta Gewecke; Meike Sörensen; J Engelbert Gessner; Joachim Freihorst; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

5.  HPV16L1-attenuated Shigella recombinant vaccine induced strong vaginal and systemic immune responses in guinea pig model.

Authors:  Xiaofei Yan; Depu Wang; Fengli Liang; Ling Fu; Cheng Guo
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Use of mchI encoding immunity to the antimicrobial peptide microcin H47 as a plasmid selection marker in attenuated bacterial live vectors.

Authors:  Chee-Mun Fang; Jin Yuan Wang; Magaly Chinchilla; Myron M Levine; William C Blackwelder; James E Galen
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

7.  Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak.

Authors:  Teysir Halaby; Emre Kucukkose; Axel B Janssen; Malbert R C Rogers; Dennis J Doorduijn; Adri G M van der Zanden; Nashwan Al Naiemi; Christina M J E Vandenbroucke-Grauls; Willem van Schaik
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1.

Authors:  David Baud; Françoise Ponci; Martine Bobst; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Influence of promoter, gene copy number, and preexisting immunity on humoral and cellular responses to a vectored antigen delivered by a Salmonella enterica vaccine.

Authors:  Manvendra Saxena; Peter J Coloe; Peter M Smooker
Journal:  Clin Vaccine Immunol       Date:  2008-11-12

10.  Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer.

Authors:  Archana Monie; Chien-Fu Hung; Richard Roden; T-C Wu
Journal:  Biologics       Date:  2008-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.